Results 71 to 80 of about 52,343 (282)

The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications

open access: yesPharmacy Practice, 2011
Objectives: This study aimed to explore how well Victorian pharmacists perceived they understood pharmacogenetics, their perceived capacity to counsel a patient about such testing, how they believed pharmacogenetics would impact upon their profession ...
McMahon T, Tucci J
doaj  

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni   +3 more
wiley   +1 more source

Pharmacogenetics of antidepressant response: An update

open access: yesHuman Genomics, 2009
The past few decades have witnessed much progress in the field of pharmacogenetics. The identification of the genetic background that regulates the antidepressant response has benefited from these advances.
Drago Antonio   +2 more
doaj   +1 more source

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine

open access: yesDiabetes/Metabolism Research Reviews, 2019
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
G. Mannino, F. Andreozzi, G. Sesti
semanticscholar   +1 more source

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde   +6 more
wiley   +1 more source

Pharmacogenetics of schizophrenia

open access: yesExpert Opinion on Pharmacotherapy, 2006
There is substantial unexplained interindividual variability in the drug treatment of schizophrenia. A substantial proportion of patients respond inadequately to antipsychotic drugs, and many experience limiting side effects. As genetic factors are likely to contribute to this variability, the pharmacogenetics of schizophrenia has attracted substantial
Reynolds, Gavin   +2 more
openaire   +4 more sources

Rules of Thumb for Estimating Drug Levels in Breast Milk: How Well Do They Work?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The American Academy of Pediatrics and the World Health Organization recommend exclusive breastfeeding for the first 6 months of life due to extensive benefits for the maternal–infant dyad. While over 90% of mothers initiate breastfeeding, continuation drops to 35% by 6 months, often due to concerns about medication safety.
Juliya Gasparyan   +3 more
wiley   +1 more source

CLOPIDOGREL PHARMACOGENETICS

open access: yesРациональная фармакотерапия в кардиологии, 2016
Platelets play an important role in the pathogenesis of atherosclerosis. They are involved in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element of these complications prevention in patients ...
A. N. Meshkov
doaj   +1 more source

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang   +17 more
wiley   +1 more source

Genetic Variability in Cisplatin Metabolism in Kidney Injury in Patients With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiotherapy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background This study investigated the roles of single nucleotide variants (SNVs) in genes of CDDP metabolism and their association with kidney dysfunction in patients with head and neck squamous cell carcinoma (HNSCC). Methods A total of 109 patients with locally advanced HNSCC, treated with CDDP, had renal function evaluated by serum ...
Ericka Francislaine Dias Costa   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy